Skip to main content

Advertisement

Table 2 Characteristics of non MDR and and MDR-TB patients, healthcare utilization, and cost (standard errors in parentheses), Latvia 2002

From: The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia

  MDR-TB (n=9) Non MDR-TB (n=54) p-value
Vital status, %    
Dead 6.6 3.7 .461
Alive 93.4 96.3 .461
Age, years 44.1 (1.3) 42.6 (2.5) .558
Age group, %    
<25 6.6 14.8 .105
25-64 89.0 74.1 .019
65 or over 4.4 11.1 .123
Sex, %    
Male 78.0 63.0 .050
Female 22.0 37.0 .050
Treatment success, %    
Cured 71.4 90.7 .006
Not cured 28.6 9.3 .006
Previous treatment, # (%)    
None 31 (33%) 54 (100%) <.001
First-line 55 (60%) 0 <.001
Second-line 6 (7%) 0 <.001
Hospital days, # 481.4 (25.0) 114.9 (12.6) <.001
Clinic visits, # 73.7 (13.4) 70.4 (9.2) .859
Specialist visits, # 11.0 (1.3) 5.1 (.6) <.001
Sputum smears, # 35.9 (1.3) 12.9 (.7) <.001
Sputum cultures,# 33.9 (1.4) 10.4 (.6) <.001
X-rays, # 14.1 (.8) 6.4 (.5) <.001
CT, # 1.0 (.1) .5 (.1) .011
Health care costs, 2002 USD $    
Inpatient $25,004 (1,301) $6,904 (759) <.001
Outpatient $1,672 (303) $1,443 (188) .587
Prescription medication $2,146 (115) $601 (3) <.001
Total treatment $28,821 (1,245) $8,408 (649) <.001